Loading company…
Savara develops medicines for rare respiratory diseases, including an inhaled treatment candidate for autoimmune pulmonary alveolar proteinosis.
Founded in 2007 and based in Langhorne, US, Savara develops treatments for rare respiratory diseases. Its lead candidate, inhaled molgramostim, is in Phase 3 clinical development for autoimmune pulmonary alveolar proteinosis (aPAP). The company is publicly listed on Nasdaq under the ticker SVRA and was led by CEO Matt Pauls as of November 2024. In July 2023, Savara raised USD 80 million in PIPE funding from TCG Crossover Management, Frazier Healthcare Partners, Janus Henderson Investors, Adage Capital Management, Bain Capital Life Sciences, New Enterprise Associates, and Venrock.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in